





# OFFICE OF THE MANAGING DIRECTOR ASSAM MEDICAL SERVICES CORPORATION LIMITED

Central Drug Ware House Campus, Patherquery, Narengi, Guwahati, Assam-781026 Email id: md-amscl@assam.gov.in

e-File No: 556245/11872

From: General Manager

Procurement, QC, IT, Logistics

Assam Medical Services Corporation Limited

To: Cadila Pharmaceuticals Limited

Cadila Corporate Campus, Sarkhej-Dholka Road, Bhat, Ahmedabad-382210, Gujarat.

Sub: Firm Debarment Notice for default in supply of ordered essential drugs.

#### Ref:

- 1.Tender No.: NHM-43018/2022-PROC/AMSCL/ECF: 255581/150953, Dated. 09/02/2023) & all relevant corrigendum notices issued against this tender.
- 2. Purchase orders (POs) placed from AMSCL detailed at **Annexure-A** with this letter.
- c) Several official communications were made via official mails & telephonic requests were also made for completion of supplies of ordered drugs but your company failed to start any kind of supply of life saving essential drugs.
- 3. Notice cum additional time period extension given to your company vide letters below but your company failed to start any kind of supply of life saving essential drugs. Extension details are as bellow: -
- a) 556245/5300, Date-21.09.2024
- b) 556245/6676, Date-17.11.2024
- 4. Show Cause notice (vide notice no-556245/6664, Date-22.11.2024) issued from AMSCL Authority for default in supply of essential drugs.
- 5. Your reply with a request to extend the delivery period, more than one month.
- 6. Extension issued from AMSCL Authority vide letter no 556245/8847, Date-07.01.2025 but your company failed to start any kind of supply of life saving essential drugs.
- 7. Your company requested further extension of delivery period (vide letter no-CPL/EXICOTE/2025-01/142, Date-28.01.2025 for more than a month but your company failed to start any kind of supply of life saving essential drugs.
- 8. Again your company submitted plea (vide letter no-CPL/EXICOTE/2025-02/152, Date-22.02.2025) to extend the delivery period for more than one month.

## Sir/Madam,

With reference to the subject cited above, I am to inform you that your company was awarded with the Purchase Orders of essential lifesaving drugs vide POs as detailed at **Annexure-A** to this letter (against your agreement with AMSCL vide tender under reference at Pt.1 above).

But you are not yet start any kind of supply of ordered essential drugs within the contractual delivery period (75 days from placing of PO), period with highest late delivery charges, (i.e., @2% of the value of delayed goods per week of delay or part thereof subject to a maximum of 10% of the total order value) and extended delivery period (under reference at pt.3-(a), (b). (Details on non-completion of supply report as per DVDMS portal is attached with this letter at

#### Annexure-A).

All efforts as mentioned above via several notices, extensions, official communications via mail & telephonic calls were made and enough scopes were given to your company to execute supplies of essential drugs but your company was found defaulter in terms of completion of supplies in a time bound manner causing resulted non availability & hindrance in public service and also resulted in increase in out-of-pocket expenditure of the patients.

It was observed that your first PO issued from AMSCL Authority on dated 28.02.2024 for "Streptokinase Injection 15,00,000 IU" but your company didn't even start any kind of supply. Instead of execution of supply your company submitted several extension request letters stating that due to non-availability of API you were not able to manufacture the drugs in-time. Your company initially stated that your plant was shut down till December 2024, again you have told in another letter it was till January 2025 due to upgradation of capacity. Now your company again submitted request letter referred at pt.8 (above) to extended your probable supply by another one additional month.

For Rest of the two ordered essential drugs i.e. Insulin Injections (i)Biphasic Isophane Insulin Injection 30 percent as Soluble Insulin and 70 percent as Isophane Insulin and (ii) Insulin Injection IP Soluble Insulin, Neutral Injection 40 IU/ml, also your company have stated similar instances and failed to start any kind of supply till date. Your un-professional statement being a pharmaceutical company dealing with essential/lifesaving drugs are not justified enough to grant more & more extension to your company whereas patients are suffering at Govt Hospitals of the state due to your non supply.

AMSCL Authority found that said drugs are essential in nature for needy patients getting treatment in Govt. Hospitals of the state, therefore show cause notice was served to your company vide letter under reference at pt.4 (above), whereas Non supply of ordered essential lifesaving drugs resulted hindrance in public service and patient are hereby deprived from Govt. scheme of Free Drug Services in Govt. Health facilities of the state.

Hence, in the greater public & patient interest, your company "Cadila Pharmaceuticals Limited" is hereby blacklisted and debarred from participating in any tender for 3 (three) years due to non supply of 03 nos. of ordered essential drugs (as detailed above and also in the attached Annexure-A) as per referred tender Clause No.5, Sub Clause-H, Pt.no.(ii), Pt.no. (iii) & Sub Clause-M.

The relevant administrative and financial penalty clauses of the tender under reference are detailed as below-

Clause No.5, Sub Clause-H, Pt. no.(ii) Firm Debarment: The firm shall be blacklisted and debarred from participating in any tender by the TIA or procuring agency for 3 (three) years if the company is debarred for all the items (where it has RC-"Rate Contract" for less than 3 items) or at least 3 items (where it holds RC-"Rate Contract" for more than equal to 3 items), Pt. no. (iii) Forfeiture of Performance Security: b) In case of Firm debarment: In addition to firm debarment the entire performance security deposited by the supplier shall be forfeited and apportioned towards financial penalty.

### Clause No.5, Sub Clause-M. Alternative Purchase:

i. If the empanelled supplier fails to execute the supply within the stipulated time, AMSCL is at liberty to make alternative purchase of the items for which the Purchase Orders have been placed from any other sources (such as Public Sector undertakings at their rates, empanelled bidders, and bidders who have been technically qualified in the said bid) or in the open market even at higher rates at the risk and the cost of the supplier and in such cases AMSCL shall have every right to recover the cost and impose penalty, apart from termination of the contract for the default. ii. In the event of making ALTERNATIVE PURCAHSE, the supplier will be

imposed penalty apart from forfeiture of Security Deposit. The excess expenditure over and above contracted prices incurred by AMSCL in making such purchases from any other source or from the open market shall be recovered from the Security Deposit or from any other money due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier or from his properties, as per rules.

This is for favour of your kind information.

Encl: **Annexure-A** (non-completion details of ordered drugs as per DVDMS portal as on 06.03.2025)

General Manager Procurement, QC, IT, Logistics Assam Medical Services Corporation Limited

Memo e File No.: 556245/11873-85

#### Copy to the:

- 1. Director of Medical Education, Assam for kind information.
- 2. Director of Health Services for kind information.
- 3. Executive Director, NHM, Assam for kind information.
- 4. Principal cum Chief Superintendent/Superintendent, all Medical Colleges for kind information.
- 5. Jt. DHS, all Districts for kind information.
- 6. CFO & GM (F & A), AMSCL for information & to incorporate financial penalty as mentioned above.
- 7. DDSM-all Districts and M.O i/c & Pharmacist-all Medical Colleges and office manager (Store & Transport) & Pharmacist NHM-Central Store for information.
- 8. CDAC-Noida/Guwahati team is hereby informed to deactivate the POs as detailed in the debarment notice.
- 9.Sr. Manager (IT), AMSCL for information & he is informed to upload the Debarment Notice in the AMSCL website.
- 10. P.S to the Hon'ble Minister, H & FW for kind information to the Hon'ble Minister.
- 11. P.S to the Commissioner & Secretary to the Govt. of Assam, H & FW Department & Chairman AMSCL for kind information to the Commissioner & Secretary
- 12. P.S Commissioner & Secretary to the Govt. of Assam, MERD for kind information to the Commissioner & Secretary.
- 13. P.A to the Mission Director, NHM, Assam for kind information to the Mission Director.
- 14. P.A to the Managing Director, AMSCL, Assam for kind information to the Managing Director.

-e-signed General Manager Procurement, QC, IT, Logistics Assam Medical Services Corporation Limited

# **Annexure-A**

NHM and AMSCL Guwahati PO Delivery Status DATE: 11-03-2025

TIME: 19:21:03

**Company Name: Cadila Pharmaceuticals Limited** 

Company Name: Cadila Pharmaceuticals Limited							
Item Name	PO No	PO Approval Date	Schedule Delivery Days	Scheduled date of delivery	Ordered Qty	% of delivery	Days passed since approval
Streptokinase Injection 15,00,000 IU	2020102384011	28-02-2024	75	12-05-2024	630	0	377
Insulin Injection IP Soluble Insulin , Neutral Injection 40 IU/ml	2020102384475	26-06-2024	75	08-09-2024	8640	0	257
Biphasic Isophane Insulin Injection 30 percent as Soluble Insulin and 70 percent as Isophane Insulin	2020102384493	26-06-2024	75	08-09-2024	8610	0	257
Streptokinase Injection 15,00,000 IU	2020102384722	27-06-2024	75	09-09-2024	410	0	256
Insulin Injection IP Soluble Insulin , Neutral Injection 40 IU/ml	2020102385379	23-09-2024	75	06-12-2024	8640	0	168
Biphasic Isophane Insulin Injection 30 percent as Soluble Insulin and 70 percent as Isophane Insulin	2020102385382	23-09-2024	75	06-12-2024	8600	0	168
Insulin Injection IP Soluble Insulin , Neutral Injection 40 IU/ml	2020102386193	03-11-2024	75	16-01-2025	3245	0	127